Pro-inflammatory mediators and oxidative stress in liver transplantation patients

Yung-Fong Tsai0 个研究点目标入组 40 人开始时间: 2013年1月21日最近更新: 2020年1月13日

试验速览

暂无简介。

•1. Participant is >=18 years of age at the time of informed consent.
•2. Participant is a male or non-pregnant, non-lactating female.
•3. Participant is either:
•i. a patient diagnosed with end stage liver failure by a physician according to the standard diagnostic criteria; or
•ii. a healthy subject with no clinically significant conditions.
•4. Participant is aware of the study procedures and the risks involved and voluntarily agrees to participate by providing written informed consent.

•1. Patients with sepsis, shock, hepatoencephalopathy, hepatorenal syndrome, severe pulmonary hypertension (>35mmHg), or antioxidants taking recently, as well as patients with massive ascites or pleural effusion were excluded.
•2. Participant has a history or current evidence of any condition, therapy or laboratory abnormality that, in the opinion of the investigator, might affect the results of the study or may not be in the best interest of the individual to participate.
•3. Participant has participated in a clinical trial within 2 months of study participation that, in the opinion of the investigator, might affect the results of the study or may not be in the best interest of the individual to participate.

发起方

Yung-Fong Tsai